Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5725-5735

  Chai, Stella ^a   Tong, Man ^a   Ng, Kai Yu ^a   Kwan, Pak Shing ^a   Chan, Yuen Piu ^a   Fung, Tsun Ming ^a   Lee, Terence K ^a,b,c   Wong, Nathalie ^d   Xie, Dan ^e   Yuan, Yun Fei ^e   Guan, Xin Yuan ^a,b,c   Ma, Stephanie ^a,b,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CD133; MiR 142 3p; Tumor initiating cells

Indexed keywords

CD133 ANTIGEN; MICRORNA; MICRORNA 142 3P; UNCLASSIFIED DRUG; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MIRN142 MICRORNA, HUMAN; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; CELL RENEWAL; COMPUTER MODEL; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; HUMAN CELL; LIVER CANCER; LUCIFERASE ASSAY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; REGULATORY MECHANISM; TUMOR INVASION; TUMOR VASCULARIZATION; ANIMAL; GENETIC TRANSFECTION; GENETICS; HEPG2 CELL LINE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; XENOGRAFT;

ANIMALS; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; GLYCOPROTEINS; HEP G2 CELLS; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; MICRORNAS; NEOPLASTIC STEM CELLS; PEPTIDES; TRANSFECTION;

EID: 84906267149     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2167     Document Type: Article

References (24)

1. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-2556.
2. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27: 1749-1758.
3. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng IO, Man K, Wong N, To KF, Zheng BJ, Lai PB, Lo CM, Chan KW, Guan XY. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010; 7: 694-707.
4. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To KF, Lai PB, Lo CM, Guan XY, Chan KW. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012; 55: 807-820.
5. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351: 820-824.
6. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007; 120: 1444-1450.
7. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008; 62: 1212-1218.
8. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 2010; 126: 2067-2078.
9. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, Yang GH, Ji Y, Fan J. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumor angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010; 59: 953-962.
10. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
11. Hernandez-Vargas H, Sincic N, Ouzounova M, Herceg Z. Epigenetic signatures in stem cells and cancer stem cells. Epigenomics 2009; 1; 261-280.
12. Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009; 10: 116-125.
13. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, Qin LX, Yang W, Wang HY, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50: 472-80.
14. Zhang J, Luo N, Luo Y, Peng Z, Zhang T, Li S. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol 2012; 40: 747-756.
15. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9: 50-63.
16. Zhang C, Xu Y, Zhao J, Fan L, Jiang G, Li R, Ling Y, Wu M, Wei L. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma. Ann Surg Oncol 2011; 18: 2373-2380.
17. You H, Ding W, Rountree CB. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010; 51: 1635-1644.
18. Wu L, Cai C, Wang X, Liu M, Li X, Tang H. MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Lett 2011;585: 1322-1330.
19. Shen WW, Zeng Z, Zhu WX, Fu GH. miR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl) 2013; 91: 989-1000.
20. Brown JJ, Parashar B, Moshage H, Tanaka KE, Engelhardt D, Rabbani E, Roy-Chowdhry N, Roy-Chowdhury J. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. Hepatology 2000; 31: 173-181.
21. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42: 3858-3863.
22. Blagosklonny MV. Cancer stem cell and cancer stemloids. Cancer Biol Ther 2007; 6: 1684-1690.
23. Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia 2006; 20: 385-391.
24. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-296.